Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026
Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Fineline Cube Jul 1, 2026
Company Drug

Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma

Fineline Cube Jul 12, 2022

Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...

Company Drug

Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL

Fineline Cube Jul 12, 2022

Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...

Company Drug

Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors

Fineline Cube Jul 12, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...

Company Deals

Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases

Fineline Cube Jul 11, 2022

China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...

R&D

Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment

Fineline Cube Jul 11, 2022

Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...

Company

CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development

Fineline Cube Jul 11, 2022

US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...

Company

Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal

Fineline Cube Jul 11, 2022

China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...

Company Legal / IP

Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001

Fineline Cube Jul 11, 2022

US-based Acer Therapeutics Inc. (Nasdaq: ACER) and Swiss partner Relief Therapeutics Holding SA (SWX: RLF)...

Company Deals

Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech

Fineline Cube Jul 11, 2022

Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...

Company Drug

OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC

Fineline Cube Jul 11, 2022

Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...

Company Drug

Hengrui Medicine’s SHR8554 Accepted for NMPA Review in Postoperative Pain

Fineline Cube Jul 11, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its market filing for SHR8554,...

R&D

Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics

Fineline Cube Jul 11, 2022

China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...

Company Drug

CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review

Fineline Cube Jul 11, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Ultra-Long-Acting Insulin Receives Clinical Trial Approval

Fineline Cube Jul 11, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product...

Company Deals

Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions

Fineline Cube Jul 11, 2022

Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB...

Policy / Regulatory

NMPA Issues New Vaccine Manufacturing and Distribution Rules

Fineline Cube Jul 11, 2022

China’s National Medical Products Administration (NMPA) has released the “Vaccine Manufacturing and Distribution Management Measures,”...

Company Drug

VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US

Fineline Cube Jul 11, 2022

China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study...

Company Deals

Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact

Fineline Cube Jul 11, 2022

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...

Company Deals

Hangzhou DAC Bio Partners with Janssen on ADC Development Deal

Fineline Cube Jul 11, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...

Policy / Regulatory

NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms

Fineline Cube Jul 8, 2022

The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...

Posts pagination

1 … 674 675 676 … 689

Recent updates

  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
  • Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.